RLMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Relmada Therapeutics Inc (RLMD) does not present a strong buy opportunity for a beginner investor with a long-term focus at this time. While there are positive catalysts such as insider buying and optimistic analyst ratings, the company's financial performance, lack of recent news, and technical indicators suggest a cautious approach. The absence of strong proprietary trading signals further supports holding off on investment for now.
The technical indicators show a bullish trend with MACD positively expanding and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, RSI at 77.556 is approaching overbought territory, and the stock is trading near resistance levels (R1: 7.456, R2: 7.78). The stock has a 60% chance of declining in the short term based on candlestick pattern analysis.
Insider buying has increased significantly (1133.44% over the last month).
Analysts have provided optimistic ratings, with price targets ranging from $8 to $19, citing the potential of NDV-01 as a best-in-class treatment.
Bullish technical indicators such as MACD and moving averages.
Financial performance remains weak, with no revenue growth and a net loss of -$19.87M in Q4
EPS dropped significantly (-46.77% YoY).
No recent news or event-driven catalysts to support immediate growth.
Stock trend analysis predicts a short-term decline in price.
In Q4 2025, the company reported no revenue growth and a net loss of -$19.87M, which improved slightly by 6.49% YoY. EPS dropped by -46.77% YoY to -0.33, indicating continued financial struggles.
Analysts are optimistic about RLMD, with multiple firms initiating coverage or upgrading the stock to Buy/Outperform ratings. Price targets range from $8 to $19, driven by the potential of NDV-01 in addressing non-muscle invasive bladder cancer. Analysts highlight the drug's sustained-release formulation and significant market opportunity.
